NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Forecast, Price & News $22.53 +0.15 (+0.67%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$22.24▼$22.7450-Day Range$22.08▼$24.8952-Week Range$14.89▼$30.22Volume219,234 shsAverage Volume363,971 shsMarket Capitalization$779.54 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Collegium Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside55.3% Upside$35.00 Price TargetShort InterestBearish19.15% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.81Based on 5 Articles This WeekInsider TradingSelling Shares$1.11 M Sold Last QuarterProj. Earnings Growth16.05%From $4.86 to $5.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector310th out of 1,018 stocksPharmaceutical Preparations Industry132nd out of 498 stocks 3.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Collegium Pharmaceutical has a forecasted upside of 55.3% from its current price of $22.53.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.15% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 2.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 2.7 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Collegium Pharmaceutical this week, compared to 2 articles on an average week.Search Interest6 people have searched for COLL on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,107,834.00 in company stock.Percentage Held by InsidersOnly 3.69% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 16.05% in the coming year, from $4.86 to $5.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -26.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -26.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 0.23. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Collegium Pharmaceutical (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.Read More Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Stock News HeadlinesMay 27, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Raised to Buy at StockNews.comMay 25, 2023 | seekingalpha.comCollegium: Turning More Constructive, Especially At 4.4x EarningsMay 27, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 23, 2023 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Ironwood Pharma (IRWD)May 18, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at StockNews.comMay 10, 2023 | americanbankingnews.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post FY2023 Earnings of $5.11 Per Share, Cantor Fitzgerald ForecastsMay 10, 2023 | marketwatch.com2030, Allergy Treatment Market ResearchMay 10, 2023 | americanbankingnews.comStockNews.com Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to "Buy"May 27, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 9, 2023 | finance.yahoo.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call TranscriptMay 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), ANI Pharmaceuticals (ANIP) and Theravance Biopharma (TBPH)May 5, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Ironwood Pharma (IRWD)May 5, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Collegium Pharmaceutical (COLL)May 5, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on Collegium Pharmaceutical, Inc.'s Q1 2023 Earnings (NASDAQ:COLL)May 4, 2023 | finance.yahoo.comCollegium Pharmaceutical (COLL) Q1 Earnings Meet EstimatesMay 4, 2023 | finance.yahoo.comCollegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to SayMay 4, 2023 | finance.yahoo.comCollegium Reports First Quarter 2023 Financial ResultsMay 4, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Horizon Therapeutics (HZNP), Lumos Pharma (LUMO) and Pacira Pharmaceuticals (PCRX)May 3, 2023 | finance.yahoo.comPacira (PCRX) Lags Q1 Earnings EstimatesMay 3, 2023 | americanbankingnews.comCollegium Pharmaceutical (COLL) to Release Earnings on ThursdayApril 28, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) PT Lowered to $35.00 at Piper SandlerApril 27, 2023 | benzinga.comCollegium Pharmaceutical Stock (NASDAQ:COLL), DividendsApril 25, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)April 22, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from Needham & Company LLCApril 20, 2023 | finance.yahoo.comCollegium to Report First Quarter 2023 Financial Results on May 4, 2023April 19, 2023 | msn.comNeedham Reiterates Collegium Pharmaceutical (COLL) Buy RecommendationApril 11, 2023 | finance.yahoo.comCollegium to Participate in 22nd Annual Needham Virtual Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Company Calendar Last Earnings5/04/2023Today5/27/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+55.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E Ratio4.64 P/E Growth0.23Net Income$-25,000,000.00 Net Margins-5.59% Pretax Margin-5.82% Return on Equity62.88% Return on Assets10.01% Debt Debt-to-Equity Ratio3.42 Current Ratio1.21 Quick Ratio1.13 Sales & Book Value Annual Sales$463.93 million Price / Sales1.68 Cash Flow$8.22 per share Price / Cash Flow2.74 Book Value$5.20 per share Price / Book4.33Miscellaneous Outstanding Shares34,600,000Free Float33,318,000Market Cap$779.54 million OptionableOptionable Beta0.81 Key ExecutivesJoseph J. CiaffoniPresident, Chief Executive Officer & DirectorColleen TupperChief Financial Officer & Executive Vice PresidentScott SudduthExecutive Vice President-Technical OperationsThomas B. SmithChief Medical Officer & Executive Vice PresidentScott DreyerChief Commercial Officer & Executive VPKey CompetitorsDyne TherapeuticsNASDAQ:DYNARS PharmaceuticalsNASDAQ:SPRYCogent BiosciencesNASDAQ:COGTAvidity BiosciencesNASDAQ:RNAPharming GroupNASDAQ:PHARView All CompetitorsInsiders & InstitutionsBrandywine Global Investment Management LLCBought 4,935 shares on 5/25/2023Ownership: 1.083%Ameriprise Financial Inc.Sold 3,861 shares on 5/22/2023Ownership: 0.379%JPMorgan Chase & Co.Bought 4,061 shares on 5/18/2023Ownership: 0.368%New York State Common Retirement FundSold 8,199 shares on 5/18/2023Ownership: 0.049%Advisory Services Network LLCSold 1,145 shares on 5/17/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions COLL Stock - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price forecast for 2023? 2 analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $35.00 to $35.00. On average, they expect the company's share price to reach $35.00 in the next year. This suggests a possible upside of 55.3% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2023? Collegium Pharmaceutical's stock was trading at $23.20 on January 1st, 2023. Since then, COLL shares have decreased by 2.9% and is now trading at $22.53. View the best growth stocks for 2023 here. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings data on Thursday, May, 4th. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.20 by $0.02. Collegium Pharmaceutical had a negative net margin of 5.59% and a positive trailing twelve-month return on equity of 62.88%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), SPDR S&P Pharmaceuticals ETF (XPH), Invesco DWA Healthcare Momentum ETF (PTH), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Pacer US Small Cap Cash Cows 100 ETF (CALF), Distillate Small/Mid Cash Flow ETF (DSMC) and Invesco S&P SmallCap 600 Pure Growth ETF (RZG). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $569.68 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.80%), Rubric Capital Management LP (9.46%), Principal Financial Group Inc. (4.48%), State Street Corp (3.91%), Renaissance Technologies LLC (3.49%) and Dimensional Fund Advisors LP (2.77%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $22.53. How much money does Collegium Pharmaceutical make? Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $779.54 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. How many employees does Collegium Pharmaceutical have? The company employs 152 workers across the globe. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com. This page (NASDAQ:COLL) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.